MAGE-1 (Target for Cancer Immunotherapy) MBS438965 from MyBioSource.com

Product Specs
ItemMAGE-1 (Target for Cancer Immunotherapy)
CompanyMyBioSource.com
Price $275.00Supplier Page View Company Product Page
Catalog NumberMBS438965
Quantity0.1 mg
ApplicationsFlow Cytometry (FC/FACS), Immunofluorescence (IF), Immunohistochemistry (IHC) Formalin
ConcentrationPurified Ab with BSA and Azide at 200ug/ml
Conjugate/TagUnconjugated
Format200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml
ReactivityHuman
TargetMAGE-1
IsotypeIgG1 kappa
Molecular WeightAntigen: 42-46kDa
CloneMZ2E/838
HostMouse
ImmunogenRecognizes a protein of 42-46kDa, identified as MAGE-1. This MAb does not cross-react with other members of MAGE-family. Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL). The MAGE family of genes codes an important group of antigens. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs). Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy
NCBI Full Gene Namemelanoma antigen family A1
NCBI Gene AliasesCT1.1, MAGE1
ClonalityMonoclonal